In breast cancer, ROS mediate EGFR-tyrosine kinase inhibitor gefitinib resistance, and the hydrogen peroxide scavenger catalase was able to sensitize those cells to gefitinib treatment [119]. Here, EGFR is linked to breast carcinoma.